Cureus

Possible connection between diabetes drug semaglutide and sudden vision nerve damage: a case report

Updated

Abstract

A case of non-arteritic anterior ischemic optic neuropathy (NAION) occurred in a young patient with diabetes receiving semaglutide, a GLP-1 receptor agonist.

  • Symptoms of NAION completely resolved after stopping semaglutide.
  • Emerging evidence suggests a potential increase in NAION incidence among users of GLP-1 receptor agonists.
  • Further studies are needed to clarify the relationship between GLP-1 RAs and NAION.
  • Identifying risk factors and developing monitoring strategies for patients on GLP-1 RAs is essential.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

Human subjects: Informed consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free